Ignite Creation Date:
2024-05-05 @ 10:42 PM
Last Modification Date:
2024-10-26 @ 10:22 AM
Study NCT ID:
NCT01164696
Status:
COMPLETED
Last Update Posted:
2010-08-24
First Post:
2010-07-16
Brief Title:
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to compare hematological toxicity costs health-related quality of Life HR-QOL and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma NHL population receiving 90Y-Zevalin with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ZV0710BE | None | None | None |